Reyners, A K L <br/><br/>
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Nov 2012 
 - 2896-2902 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mds107  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Carboplatin--administration & dosage<br/>Carcinoma, Ovarian Epithelial<br/>Celecoxib<br/>Cyclooxygenase 2 Inhibitors--adverse effects<br/>Disease-Free Survival<br/>Docetaxel<br/>Fallopian Tube Neoplasms--drug therapy<br/>Female<br/>Humans<br/>Middle Aged<br/>Neoplasm Staging<br/>Neoplasms, Glandular and Epithelial--drug therapy<br/>Ovarian Neoplasms--drug therapy<br/>Peritoneal Neoplasms--drug therapy<br/>Pyrazoles--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Taxoids--administration & dosage